Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3
Go back to Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3| (NASDAQ: LABT) | Delayed: 3.00 -0.41 (12.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.41 | 52 Week High | $ | |||
| Open | $3.55 | 52 Week Low | $ | |||
| Day High | $3.55 | P/E | N/A | |||
| Day Low | $2.77 | EPS | $ | |||
| Volume | 1,779,145 | |||||
